RhIGF-1 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 156 | Rett syndrome | 2 |
156. Rett syndrome
Clinical trials : 40 / Drugs : 53 - (DrugBank : 19) / Drug target genes : 77 - Drug target pathways : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01777542 (ClinicalTrials.gov) | January 2013 | 23/1/2013 | Treatment of Rett Syndrome With Recombinant Human IGF-1 | Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection) | Rett Syndrome | Drug: Recombinant Human Insulin Growth Factor 1 (rhIGF-1);Drug: Placebo | Boston Children's Hospital | International Rett Syndrome Foundation | Completed | 2 Years | 10 Years | Female | 30 | Phase 2 | United States |
| 2 | NCT01253317 (ClinicalTrials.gov) | December 2010 | 2/12/2010 | Treatment of Rett Syndrome With rhIGF-1 (Mecasermin [rDNA]Injection) | Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With IGF-1 | Rett Syndrome | Drug: rhIGF-1 | Boston Children’s Hospital | International Rett Syndrome Foundation;Autism Speaks | Completed | 2 Years | 12 Years | Female | 12 | Phase 1 | United States |